Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report ; volume:6 ; number:1 ; day:14 ; month:6 ; year:2018 ; pages:1-5 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (14.6.2018), 1-5, 12.2018
- Creator
-
Clark, Joseph I.
- Contributor
-
Bufalino, Shams
Singh, Shruti
Borys, Ewa
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0370-6
- URN
-
urn:nbn:de:101:1-2018082219085225640868
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Clark, Joseph I.
- Bufalino, Shams
- Singh, Shruti
- Borys, Ewa
- SpringerLink (Online service)
Other Objects (12)
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
Omeprazole-associated rhabdomyolysis
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Interleukin 32 expression in human melanoma
Rhabdomyolysis induced by nelarabine
Perspectives on Exertional Rhabdomyolysis
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Rhabdomyolysis in drug-related deaths
Pazopanib and Statin-Induced Rhabdomyolysis
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
Omeprazole-associated rhabdomyolysis
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Interleukin 32 expression in human melanoma
Rhabdomyolysis induced by nelarabine
Perspectives on Exertional Rhabdomyolysis
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Rhabdomyolysis in drug-related deaths
Pazopanib and Statin-Induced Rhabdomyolysis
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Towards the generation of novel natural killer cell-based immunotherapies against melanoma
Towards the Generation of novel Natural Killer Cell-based Immunotherapies against Melanoma
Omeprazole-associated rhabdomyolysis
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review
Interleukin 32 expression in human melanoma
Rhabdomyolysis induced by nelarabine
Perspectives on Exertional Rhabdomyolysis
Immunotherapies in solid tumors
Immunotherapies in rare cancers
Rhabdomyolysis in drug-related deaths